CVRX · CVRx, Inc.
$2.84
+0.02 (+0.71%)
At close · Aug 20
Market Cap
$74.73M
Shares
26.64M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.84
Open$2.81
Day$2.77–2.95
52W close$2.37–10.81
Avg vol 30d1.1M
Short int2.0M · 7.5% float · 7.9d
Short vol44%
Last earningsAug 6, 2026
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−40%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−42%
trailing
6-month return
−65%
trailing
YTD return
−60%
this year
Relative strength
−76%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$76.4K over 90 days · 0% sells
Short interest
Rising
7.54% of float · ▲ +4.3% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
88 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
85%
expanding
EPS growth
+23%
Y/Y
Free cash flow
$-40.8M
Balance sheet
$26.2M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
15.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year of 2026
Total revenue
Initiated
$58M – $60M
prior FY $56.65M
midpoint +4.1% Y/Y
Gross margin
Initiated
86% – 87%
Operating expenses
Initiated
$99M – $101M
third quarter of 2026
Total revenue
Initiated
$13.5M – $14.5M
prior qtr $15.71M
midpoint −10.9% QoQ
Prior guidance
period ended
· from the 8-K filed May 11, 2026
Total revenue
· second quarter of 2026
$15.1M – $16.1M
Guided vs delivered
· last 8 settled
Total revenue between $13.7 million and $14.7 million
first quarter of 2026
guided $13.7M – $14.7M
$14.77M
Beat +4.0%
Total revenue
full year of 2025
guided $55.6M – $56.6M
$56.65M
Beat +1.0%
Total revenue
fourth quarter of 2025
guided $15M – $16M
$16.02M
Beat +3.4%
Total revenue
third quarter of 2025
guided $13.7M – $14.7M
$14.69M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−40%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$76.4K over 90 days · 0% sells
Short interest
Rising
7.54% of float · ▲ +4.3% MoM · 7.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
88 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 6%
Range high $11
vs 200-day avg -59%
vs 50-day avg -40%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active implanting centers in the U.S. | 258 | Q2 2026 | — |
|
|
|||
| Revenue units in the U.S. | 466 | Q2 2026 | — |
|
|
|||
| Sales territories in the U.S. | 56 | Q2 2026 | — |
|
|
|||
| Total revenue units in Europe | 40 | Q2 2026 | — |
|
|
|||
| 30-day approval rate for Medicare Advantage prior authorizations | 50% | first two months of 2026 | — |
| Active implanting centers | 252 | Full Year 2025 | — |
| Revenue units in Europe | 219 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVRX
this stock
CVRx, Inc.
|
$74.73M | -60.0% | +10.4% | — | 7.5% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVRX | -3.4% | -41.9% | -65.2% | -45.1% | -60.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -1.4% | -45.2% | -76.4% | -47.2% | -71.8% |
Key facts
CIK
1235912
CUSIP
126638105
13F (30d)
83 filings
83 filers
Visit website
Investor relations